Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management
出版年份 2017 全文链接
标题
Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 08, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2017-01-30
DOI
10.3389/fphar.2017.00019
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy
- (2016) Paul J. Hesketh et al. CANCER
- Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan
- (2016) Yoshifumi Baba et al. DISEASES OF THE ESOPHAGUS
- Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy
- (2016) Bernardo Rapoport et al. EUROPEAN JOURNAL OF CANCER
- The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting
- (2016) Rudolph M. Navari Expert Opinion On Drug Safety
- Antiemetics: American Society of Clinical Oncology Focused Guideline Update
- (2016) Paul J. Hesketh et al. JOURNAL OF CLINICAL ONCOLOGY
- Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
- (2016) Rudolph M. Navari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting
- (2016) Rudolph M. Navari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance)
- (2016) Lisa Kottschade et al. SUPPORTIVE CARE IN CANCER
- Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis
- (2016) Leonard Chiu et al. SUPPORTIVE CARE IN CANCER
- Risk Model–Guided Antiemetic Prophylaxis vs Physician’s Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer
- (2016) Mark Clemons et al. JAMA Oncology
- Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial
- (2015) C. Weinstein et al. ANNALS OF ONCOLOGY
- Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
- (2015) K. Jordan et al. ANNALS OF ONCOLOGY
- 1529 Low risk of drug interactions when rolapitant is coadministered with CYP2D6 or BCRP substrates: Integrated safety results
- (2015) S. Barbour et al. EUROPEAN JOURNAL OF CANCER
- Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial
- (2015) Lee S Schwartzberg et al. LANCET ONCOLOGY
- Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials
- (2015) Bernardo L Rapoport et al. LANCET ONCOLOGY
- Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?
- (2015) T. L. Ng et al. ONCOLOGIST
- Role of Psychosocial Variables on Chemotherapy-Induced Nausea and Vomiting and Health-Related Quality of Life among Cancer Patients: A European Study
- (2015) Luigi Grassi et al. PSYCHOTHERAPY AND PSYCHOSOMATICS
- Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
- (2015) Yolanda Escobar et al. SUPPORTIVE CARE IN CANCER
- Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial
- (2015) Masakazu Abe et al. SUPPORTIVE CARE IN CANCER
- Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)
- (2015) Bernardo Rapoport et al. SUPPORTIVE CARE IN CANCER
- Biological and Pharmacological Aspects of the NK1-Receptor
- (2015) Susana Garcia-Recio et al. Biomed Research International
- Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
- (2014) P. J. Hesketh et al. ANNALS OF ONCOLOGY
- A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
- (2014) R. J. Gralla et al. ANNALS OF ONCOLOGY
- A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
- (2014) M. Aapro et al. ANNALS OF ONCOLOGY
- Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy—a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines
- (2014) Shiying Yu et al. SUPPORTIVE CARE IN CANCER
- Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2,388 health care providers
- (2014) Emily S. Van Laar et al. SUPPORTIVE CARE IN CANCER
- Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries
- (2014) Ruey Kuen Hsieh et al. SUPPORTIVE CARE IN CANCER
- Antiemetic Guideline Consistency and Incidence of Chemotherapy-Induced Nausea and Vomiting in US Community Oncology Practice: INSPIRE Study
- (2014) James W. Gilmore et al. Journal of Oncology Practice
- International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): Content and implementation in daily routine practice
- (2013) Karin Jordan et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The role of vagal neurocircuits in the regulation of nausea and vomiting
- (2013) Tanja Babic et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Prospective Observational Study
- (2013) Alexander Molassiotis et al. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
- The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)
- (2012) M. Aapro et al. ANNALS OF ONCOLOGY
- Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer
- (2012) Daniel R. Gomez et al. CANCER
- Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE
- (2011) Steven Grunberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2011) Ethan Basch et al. JOURNAL OF CLINICAL ONCOLOGY
- Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting
- (2011) Henning Burmeister et al. SUPPORTIVE CARE IN CANCER
- Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study
- (2011) Doranne L. Hilarius et al. SUPPORTIVE CARE IN CANCER
- Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting
- (2010) Thomas A. Burke et al. SUPPORTIVE CARE IN CANCER
- Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
- (2009) Lijun Tan et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study
- (2009) Bernardo L. Rapoport et al. SUPPORTIVE CARE IN CANCER
- Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy
- (2009) Eva Ellebæk et al. Current Opinion in Supportive and Palliative Care
- Chemotherapy-Induced Nausea and Vomiting
- (2008) Paul J. Hesketh NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started